Genzyme GENZ

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Sanofi Shakes Off Patent Losses

      Headlines

      Mon, 24 Nov 2014

      acquisitions are likely to slow in the near term following the Genzyme deal, we expect that over the long term Sanofi will continue ..... Viehbacher executed several acquisitions (such as Merial and Genzyme ) to create favorable returns on the capital deployed

    2. Sanofi's Board of Directors Ousts CEO, Leading to Stewardship Downgrade; No Change to Fair Value

      Commentary

      Wed, 29 Oct 2014

      strategic decisions made during his tenure. For example, Viehbacher executed several acquisitions (such as Merial and Genzyme ) to create favorable returns on the capital deployed. Nevertheless, the board's continued commitment to Sanofi's

    3. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      continues. I think there is going to be a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase

      Genzyme found at 3:20

      a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase growth and do
    4. Invest With These Exemplary Management Teams

      Headlines

      Sun, 26 May 2013

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    5. Sanofi's 4Q and 2013 Guidance Match Our Projections but Fall Short of Consensus Expectations

      Commentary

      Thu, 7 Feb 2013

      quarterly results. The company's updated guidance on an improving pipeline along with steady growth from emerging markets, Genzyme products, consumer health, vaccines, and diabetes drugs increases our conviction behind our wide moat rating for the

    6. Sanofi Posts Solid 3Q Supported by Cost-Containment Efforts, but No Change to Valuation

      Commentary

      Thu, 25 Oct 2012

      growth continued to perform well, with particular strength from diabetes drug Lantus, which was up 18% year over year. Genzyme products and emerging markets also continued to post steady gains. However, generic competition to cardiovascular drug

    7. LabCorp Adds to its Reference Lab Network with Medtox Scientific

      Commentary

      Tue, 5 Jun 2012

      challenging macroeconomic conditions. LabCorp's purchases of Genzyme Genetics' diagnostics unit and Orchid Cellmark in 2010 ..... times sales for Medtox, and it paid 2.5 times sales for Genzyme 's diagnostics in 2010--considerably lower compared

    8. Sanofi Posts Strong First Quarter as Cost-Cutting Helps Buoy the Bottom Line

      Commentary

      Fri, 27 Apr 2012

      year period, which was expected, as the addition of Genzyme products and strong growth from diabetes drug Lantus helped ..... remainder of the year will see revenue declines as the Genzyme acquisition annualizes and generic competition continues

    9. LabCorp's 4Q Held no Surprises, but we Expect Mild Volume Improvement in 2012

      Commentary

      Fri, 10 Feb 2012

      primarily driven by its acquisition of Genzyme Genetics. Total quarterly volume ..... seen since 2010), the addition of Genzyme Genetics boosted both volume and ..... requisition. Conversely, once the Genzyme Genetics component is removed from

    10. Shire's 2011 Performance In Line, 2012 Guidance Could Be Difficult to Meet

      Commentary

      Thu, 9 Feb 2012

      s Human Genetic Therapies segment where we see potential weakness going forward, largely due to the return of Sanofi ( Genzyme ) as a competitive threat. Not only is the new Fabrazyme manufacturing facility now approved, but Sanofi expects to release

    « Prev12345Next »
    Content Partners